+Follow
gyudon
No personal profile
4
Follow
1
Followers
1
Topic
0
Badge
Posts
Hot
gyudon
03-21
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
gyudon
02-16
Singapore Stocks to Watch: ThaiBev, Keppel, Seatrium, Civmec
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3579080037721963","uuid":"3579080037721963","gmtCreate":1615991110533,"gmtModify":1615991110533,"name":"gyudon","pinyin":"gyudon","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","hatId":"ca_profile_frame_Lm11L6","hatName":"LV4 头像框","vip":1,"status":2,"fanSize":1,"headSize":4,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.13","exceedPercentage":"60.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.36%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":286404122255576,"gmtCreate":1710957589701,"gmtModify":1710957833391,"author":{"id":"3579080037721963","authorId":"3579080037721963","name":"gyudon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579080037721963","authorIdStr":"3579080037721963"},"themes":[],"htmlText":"","listText":"","text":"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/286404122255576","repostId":"2420474539","repostType":2,"repost":{"id":"2420474539","pubTimestamp":1710764340,"share":"https://ttm.financial/m/news/2420474539?lang=&edition=fundamental","pubTime":"2024-03-18 20:19","market":"us","language":"en","title":"Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM","url":"https://stock-news.laohu8.com/highlight/detail?id=2420474539","media":"Zacks","summary":"Exact Sciences CorporationEXAS recently announced the online publication of the BLUE-C study results in The New England Journal of Medicine . The 20,000-participant, multi-center and prospective study was designed to determine the performance characteristics of the company’s next-generation Cologuard Plus multitarget stool DNA test.The publication of the \"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening\" peer-reviewed study in NEJM reflects a decade of Exact Sciences’ deep scientific and medical research in collaboration with Mayo Clinic.Significance of the Cologuard Plus and BLUE-C Study. Exact Sciences and Mayo Clinic collaboratively developed Cologuard Plus, which features novel biomarkers and improved laboratory processes. It also incorporates enhanced sample stability components to provide patients more time to return their samples to EXAS' lab and increase the valid result rate. With CRC widely accepted as the most common and preventable cancer globally","content":"<html><body><p><strong>Exact Sciences Corporation </strong>EXAS recently announced the online publication of the BLUE-C study results in The New England Journal of Medicine (NEJM). The 20,000-participant, multi-center and prospective study was designed to determine the performance characteristics of the company’s next-generation Cologuard Plus multitarget stool DNA test.</p>\n<p>The publication of the \"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer (CRC) Screening\" peer-reviewed study in NEJM reflects a decade of Exact Sciences’ deep scientific and medical research in collaboration with Mayo Clinic.</p>\n<h3>Significance of the Cologuard Plus and BLUE-C Study</h3>\n<p>Exact Sciences and Mayo Clinic collaboratively developed Cologuard Plus, which features novel biomarkers and improved laboratory processes. It also incorporates enhanced sample stability components to provide patients more time to return their samples to EXAS' lab and increase the valid result rate. With CRC widely accepted as the most common and preventable cancer globally, the company is eager to bring an improved and noninvasive CRC screening test to patients in Cologuard Plus.</p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/e._UV6tYCwtWLpDja3CwZQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/df19c6b85eee776297c46e0a615b334a\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<p>One of the largest CRC screening trials ever conducted, the BLUE-C study design directly compared Cologuard Plus and an independent fecal immunochemical test (FIT), using colonoscopy as a reference method. The study investigators also collected blood samples for evaluation of a blood-based CRC screening test developed by Exact Sciences. Further, the study cohort was diverse and reflective of the population in the United States, which ensured that the BLUE-C findings and Cologuard Plus are relevant for all screen-eligible individuals, regardless of race or ethnicity.</p>\n<p>The pre-market approval application for Cologuard Plus was submitted to the FDA in December 2023, and Exact Sciences plans to make the test available in 2025, pending approval.</p>\n<h3>More on the Study Outcome</h3>\n<p>The BLUE-C study results demonstrated that Cologuard Plus met all the endpoints, achieving 94% CRC sensitivity, 91% specificity including non-advanced findings, and 93% specificity including no findings. Specificity was even better in younger age groups, at 96% in the 45-54 year olds. Cologuard Plus will minimize unnecessary follow-up colonoscopies by reducing the likelihood of a false-positive screening test.</p>\n<p>The outcome also showed that Cologuard Plus significantly outperformed an independent FIT for overall CRC sensitivity, treatable-stage CRC (stages I-III) sensitivity, high-grade dysplasia sensitivity and advanced precancerous lesion sensitivity. To potentially expand the eligible screening population beyond average-risk patients, the BLUE-C study enrolled a small subset of participants with a first-degree relative with a history of CRC.</p>\n<p>Sensitivities for CRC and advanced precancerous lesions were similar among participants with a first-degree relative with a history of CRC and those without such a relative. Among the subset of nearly 19,000 participants who were average-risk, without a first-degree relative with a history of CRC, Cologuard Plus exhibited 95% sensitivity for CRC and 43% sensitivity for advanced precancerous lesions at a 91% specificity including non-advanced findings, or 94% specificity including no findings.</p>\n<h3>Industry Prospects</h3>\n<p>Per a Research report, the CRC screening market is likely to be worth $15.48 billion in 2024 and is expected to witness a CAGR of 5.16% by 2029.</p>\n<h3>Notable Highlights</h3>\n<p>According to Exact Sciences, Cologuard has become an essential part of healthcare providers’ screening tool kit partly because of patients’ preferences and demands. The adoption of the test is being driven by brand awareness and customer loyalty, helping to reach the 60 million Americans who are not up to date with colon cancer screening.</p>\n<p>During fourth-quarter 2023, Exact Sciences continued to witness a broad-based momentum in the Cologuard adoption by healthcare providers, with an all-time high of 172,000 orders received for the screening test. Cologuard brand awareness reached an all-time high of 89%. Further, the company’s market research showed people who have never been screened prefer Cologuard 2 to 1 over colonoscopy.</p>\n<h3>Price Performance</h3>\n<p>In the past year, shares of EXAS have lost 9% compared with the industry’s decline of 7.7%.</p>\n<h3>Zacks Rank and Key Picks</h3>\n<p>Exact Sciences currently carries a Zacks Rank #3 (Hold).</p>\n<p>Some better-ranked stocks in the broader medical space are <strong>Cardinal Health</strong> (CAH), <strong>Stryker </strong>(SYK) and <strong>DaVita</strong> (DVA). While Cardinal Health and Stryker carry a Zacks Rank #2 (Buy), DaVita sports a Zacks Rank #1 (Strong Buy) at present. You can see <strong>the complete list of today’s Zacks #1 Rank stocks here</strong><strong>.</strong></p>\n<p>Cardinal Health’s stock has rallied 55.5% in the past year. Estimates for Cardinal Health’s fiscal 2024 earnings per share (EPS) have risen from $7.17 to $7.28 and from $7.94 to $8.03 in fiscal 2025 in the past 30 days.</p>\n<p>CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it posted an earnings surprise of 16.67%.</p>\n<p>Estimates for Stryker’s 2024 EPS have increased from $11.84 to $11.86 in the past 30 days. Shares of the company have moved 27.2% upward in the past year compared with the industry’s growth of 6.6%.</p>\n<p>SYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.09%. In the last reported quarter, it delivered an average earnings surprise of 5.81%.</p>\n<p>Estimates for DaVita’s 2024 EPS have moved from $8.86 to $8.97 in the past 30 days. Shares of the company have surged 75.3% in the past year compared with the industry’s 23.8% growth.</p>\n<p>DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.57%. In the last reported quarter, it delivered an average earnings surprise of 22.22%.</p>\n<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report</p>\n<p>Stryker Corporation (SYK) : Free Stock Analysis Report</p>\n<p>DaVita Inc. (DVA) : Free Stock Analysis Report</p>\n<p>Cardinal Health, Inc. (CAH) : Free Stock Analysis Report</p>\n<p>Exact Sciences Corporation (EXAS) : Free Stock Analysis Report</p>\n<p>To read this article on Zacks.com click here.</p>\n<p>Zacks Investment Research</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExact Sciences' (EXAS) BLUE-C Study Results Published in NEJM\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-18 20:19 GMT+8 <a href=https://finance.yahoo.com/news/exact-sciences-exas-blue-c-121900151.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Exact Sciences Corporation EXAS recently announced the online publication of the BLUE-C study results in The New England Journal of Medicine (NEJM). The 20,000-participant, multi-center and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exact-sciences-exas-blue-c-121900151.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","relate_stocks":{"BLUE":"bluebird bio Inc.","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","SYK":"史赛克","EXAS":"精密科学","BK4504":"桥水持仓","LU0882574055.USD":"富达全球健康医疗A ACC","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","BK4548":"巴美列捷福持仓","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","BK4213":"石油与天然气的勘探与生产","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4175":"保健护理产品经销商","LU1861558580.USD":"日兴方舟颠覆性创新基金B","FIT":"Fitbit Inc.","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD) INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4556":"基因编辑","LU0528227936.USD":"富达环球人口趋势基金A-ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","BK4566":"资本集团","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4196":"保健护理服务","BK4578":"CAR-T","BK4082":"医疗保健设备","CRC":"加州资源","DVA":"达维塔保健","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4559":"巴菲特持仓","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","BK4588":"碎股","CAH":"卡地纳健康","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC"},"source_url":"https://finance.yahoo.com/news/exact-sciences-exas-blue-c-121900151.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2420474539","content_text":"Exact Sciences Corporation EXAS recently announced the online publication of the BLUE-C study results in The New England Journal of Medicine (NEJM). The 20,000-participant, multi-center and prospective study was designed to determine the performance characteristics of the company’s next-generation Cologuard Plus multitarget stool DNA test.\nThe publication of the \"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer (CRC) Screening\" peer-reviewed study in NEJM reflects a decade of Exact Sciences’ deep scientific and medical research in collaboration with Mayo Clinic.\nSignificance of the Cologuard Plus and BLUE-C Study\nExact Sciences and Mayo Clinic collaboratively developed Cologuard Plus, which features novel biomarkers and improved laboratory processes. It also incorporates enhanced sample stability components to provide patients more time to return their samples to EXAS' lab and increase the valid result rate. With CRC widely accepted as the most common and preventable cancer globally, the company is eager to bring an improved and noninvasive CRC screening test to patients in Cologuard Plus.\nImage Source: Zacks Investment Research\nOne of the largest CRC screening trials ever conducted, the BLUE-C study design directly compared Cologuard Plus and an independent fecal immunochemical test (FIT), using colonoscopy as a reference method. The study investigators also collected blood samples for evaluation of a blood-based CRC screening test developed by Exact Sciences. Further, the study cohort was diverse and reflective of the population in the United States, which ensured that the BLUE-C findings and Cologuard Plus are relevant for all screen-eligible individuals, regardless of race or ethnicity.\nThe pre-market approval application for Cologuard Plus was submitted to the FDA in December 2023, and Exact Sciences plans to make the test available in 2025, pending approval.\nMore on the Study Outcome\nThe BLUE-C study results demonstrated that Cologuard Plus met all the endpoints, achieving 94% CRC sensitivity, 91% specificity including non-advanced findings, and 93% specificity including no findings. Specificity was even better in younger age groups, at 96% in the 45-54 year olds. Cologuard Plus will minimize unnecessary follow-up colonoscopies by reducing the likelihood of a false-positive screening test.\nThe outcome also showed that Cologuard Plus significantly outperformed an independent FIT for overall CRC sensitivity, treatable-stage CRC (stages I-III) sensitivity, high-grade dysplasia sensitivity and advanced precancerous lesion sensitivity. To potentially expand the eligible screening population beyond average-risk patients, the BLUE-C study enrolled a small subset of participants with a first-degree relative with a history of CRC.\nSensitivities for CRC and advanced precancerous lesions were similar among participants with a first-degree relative with a history of CRC and those without such a relative. Among the subset of nearly 19,000 participants who were average-risk, without a first-degree relative with a history of CRC, Cologuard Plus exhibited 95% sensitivity for CRC and 43% sensitivity for advanced precancerous lesions at a 91% specificity including non-advanced findings, or 94% specificity including no findings.\nIndustry Prospects\nPer a Research report, the CRC screening market is likely to be worth $15.48 billion in 2024 and is expected to witness a CAGR of 5.16% by 2029.\nNotable Highlights\nAccording to Exact Sciences, Cologuard has become an essential part of healthcare providers’ screening tool kit partly because of patients’ preferences and demands. The adoption of the test is being driven by brand awareness and customer loyalty, helping to reach the 60 million Americans who are not up to date with colon cancer screening.\nDuring fourth-quarter 2023, Exact Sciences continued to witness a broad-based momentum in the Cologuard adoption by healthcare providers, with an all-time high of 172,000 orders received for the screening test. Cologuard brand awareness reached an all-time high of 89%. Further, the company’s market research showed people who have never been screened prefer Cologuard 2 to 1 over colonoscopy.\nPrice Performance\nIn the past year, shares of EXAS have lost 9% compared with the industry’s decline of 7.7%.\nZacks Rank and Key Picks\nExact Sciences currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Cardinal Health (CAH), Stryker (SYK) and DaVita (DVA). While Cardinal Health and Stryker carry a Zacks Rank #2 (Buy), DaVita sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nCardinal Health’s stock has rallied 55.5% in the past year. Estimates for Cardinal Health’s fiscal 2024 earnings per share (EPS) have risen from $7.17 to $7.28 and from $7.94 to $8.03 in fiscal 2025 in the past 30 days.\nCAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it posted an earnings surprise of 16.67%.\nEstimates for Stryker’s 2024 EPS have increased from $11.84 to $11.86 in the past 30 days. Shares of the company have moved 27.2% upward in the past year compared with the industry’s growth of 6.6%.\nSYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.09%. In the last reported quarter, it delivered an average earnings surprise of 5.81%.\nEstimates for DaVita’s 2024 EPS have moved from $8.86 to $8.97 in the past 30 days. Shares of the company have surged 75.3% in the past year compared with the industry’s 23.8% growth.\nDVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.57%. In the last reported quarter, it delivered an average earnings surprise of 22.22%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nStryker Corporation (SYK) : Free Stock Analysis Report\nDaVita Inc. (DVA) : Free Stock Analysis Report\nCardinal Health, Inc. (CAH) : Free Stock Analysis Report\nExact Sciences Corporation (EXAS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":274460230590712,"gmtCreate":1708044686347,"gmtModify":1708045086900,"author":{"id":"3579080037721963","authorId":"3579080037721963","name":"gyudon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579080037721963","authorIdStr":"3579080037721963"},"themes":[],"htmlText":"","listText":"","text":"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/274460230590712","repostId":"1133055268","repostType":2,"repost":{"id":"1133055268","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings","home_visible":1,"media_name":"TigerNews SG","id":"1050470178","head_image":"https://community-static.tradeup.com/news/f17a9a7b68c877792d5e556261e9e709"},"pubTimestamp":1707958540,"share":"https://ttm.financial/m/news/1133055268?lang=&edition=fundamental","pubTime":"2024-02-15 08:55","market":"sg","language":"en","title":"Singapore Stocks to Watch: ThaiBev, Keppel, Seatrium, Civmec","url":"https://stock-news.laohu8.com/highlight/detail?id=1133055268","media":"TigerNews SG","summary":"$Thai Beverage(Y92.SI)$: Thai Beverage (ThaiBev) on Wednesday (Feb 14) said its sales revenue for the first quarter ended Dec 31, 2023 fell by 5.9 per cent to 76.1 billion baht (S$2.8 billion) from 80","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/Y92.SI\">Thai Beverage</a>: Thai Beverage (ThaiBev) on Wednesday (Feb 14) said its sales revenue for the first quarter ended Dec 31, 2023 fell by 5.9 per cent to 76.1 billion baht (S$2.8 billion) from 80.9 billion baht year on year.</p><p style=\"text-align: start;\">However, its earnings before interest, taxes, depreciation and amortisation (Ebitda) rose by 1.9 per cent to 13.8 billion baht, from 13.5 billion baht in the corresponding year-ago period, as a result of “effective cost management”, the beverage group said in a business update.</p><p style=\"text-align: start;\">The lower revenue came as the group’s beer segment revenue declined 14 per cent to 32.6 billion baht, from 37.9 billion baht in Q1 FY2023, on the back of sales volume falling by 15 per cent and a slower-than-expected economic recovery in Thailand and Vietnam.</p><p><a href=\"https://laohu8.com/S/BN4.SI\">Keppel</a>: Keppel has been appointed to design, build and operate a solar photovoltaic (PV) system on the rooftops of Changi Airport’s terminals, terminal auxiliary structures, airfield and cargo buildings for 25 years, the asset manager announced on Wednesday (Feb 14).</p><p style=\"text-align: start;\">In a joint release with Changi Airport Group (CAG), the group announced that the system will have a combined generation capacity of 43 megawatt-peak (MWp), of which 38 MWp will be installed on rooftops.</p><p style=\"text-align: start;\">This makes it the largest single-site rooftop solar PV system in Singapore, said the group.</p><p><a href=\"https://laohu8.com/S/S51.SI\">Seatrium</a> has renewed its long-term favoured customer contract with two maritime companies to repair, refurbish and upgrade a combined fleet of 43 liquefied natural gas (LNG) carriers docked in South-east Asia.</p><p style=\"text-align: start;\">The contracts, inked with GasLog LNG Services and Shell International Trading and Shipping Company, will run from 2024 to 2029, Seatrium said on Wednesday (Feb 14).</p><p style=\"text-align: start;\">They were awarded to the group’s wholly owned subsidiary, Seatrium Repairs and Upgrades. It will also support joint planning, information and experience sharing.</p><p><a href=\"https://laohu8.com/S/P9D.SI\">Civmec</a>: ENGINEERING and construction company Civmec posted a 12.9 per cent increase in net profit to A$31.9 million (S$27.9 million) for the first half ended Dec 31, 2023, on the back of higher revenue.</p><p style=\"text-align: start;\">This is up from A$28.2 million in the previous corresponding period, the Australia-headquartered company said in a bourse filing on Wednesday (Feb 14).</p><p style=\"text-align: start;\">Earnings per share came in at A$0.0629 compared to A$0.056 in the same period a year earlier.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stocks to Watch: ThaiBev, Keppel, Seatrium, Civmec</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stocks to Watch: ThaiBev, Keppel, Seatrium, Civmec\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1050470178\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/f17a9a7b68c877792d5e556261e9e709);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">TigerNews SG </p>\n<p class=\"h-time\">2024-02-15 08:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/Y92.SI\">Thai Beverage</a>: Thai Beverage (ThaiBev) on Wednesday (Feb 14) said its sales revenue for the first quarter ended Dec 31, 2023 fell by 5.9 per cent to 76.1 billion baht (S$2.8 billion) from 80.9 billion baht year on year.</p><p style=\"text-align: start;\">However, its earnings before interest, taxes, depreciation and amortisation (Ebitda) rose by 1.9 per cent to 13.8 billion baht, from 13.5 billion baht in the corresponding year-ago period, as a result of “effective cost management”, the beverage group said in a business update.</p><p style=\"text-align: start;\">The lower revenue came as the group’s beer segment revenue declined 14 per cent to 32.6 billion baht, from 37.9 billion baht in Q1 FY2023, on the back of sales volume falling by 15 per cent and a slower-than-expected economic recovery in Thailand and Vietnam.</p><p><a href=\"https://laohu8.com/S/BN4.SI\">Keppel</a>: Keppel has been appointed to design, build and operate a solar photovoltaic (PV) system on the rooftops of Changi Airport’s terminals, terminal auxiliary structures, airfield and cargo buildings for 25 years, the asset manager announced on Wednesday (Feb 14).</p><p style=\"text-align: start;\">In a joint release with Changi Airport Group (CAG), the group announced that the system will have a combined generation capacity of 43 megawatt-peak (MWp), of which 38 MWp will be installed on rooftops.</p><p style=\"text-align: start;\">This makes it the largest single-site rooftop solar PV system in Singapore, said the group.</p><p><a href=\"https://laohu8.com/S/S51.SI\">Seatrium</a> has renewed its long-term favoured customer contract with two maritime companies to repair, refurbish and upgrade a combined fleet of 43 liquefied natural gas (LNG) carriers docked in South-east Asia.</p><p style=\"text-align: start;\">The contracts, inked with GasLog LNG Services and Shell International Trading and Shipping Company, will run from 2024 to 2029, Seatrium said on Wednesday (Feb 14).</p><p style=\"text-align: start;\">They were awarded to the group’s wholly owned subsidiary, Seatrium Repairs and Upgrades. It will also support joint planning, information and experience sharing.</p><p><a href=\"https://laohu8.com/S/P9D.SI\">Civmec</a>: ENGINEERING and construction company Civmec posted a 12.9 per cent increase in net profit to A$31.9 million (S$27.9 million) for the first half ended Dec 31, 2023, on the back of higher revenue.</p><p style=\"text-align: start;\">This is up from A$28.2 million in the previous corresponding period, the Australia-headquartered company said in a bourse filing on Wednesday (Feb 14).</p><p style=\"text-align: start;\">Earnings per share came in at A$0.0629 compared to A$0.056 in the same period a year earlier.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BN4.SI":"吉宝有限公司","P9D.SI":"CIVMEC公司","Y92.SI":"泰国酿酒"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133055268","content_text":"Thai Beverage: Thai Beverage (ThaiBev) on Wednesday (Feb 14) said its sales revenue for the first quarter ended Dec 31, 2023 fell by 5.9 per cent to 76.1 billion baht (S$2.8 billion) from 80.9 billion baht year on year.However, its earnings before interest, taxes, depreciation and amortisation (Ebitda) rose by 1.9 per cent to 13.8 billion baht, from 13.5 billion baht in the corresponding year-ago period, as a result of “effective cost management”, the beverage group said in a business update.The lower revenue came as the group’s beer segment revenue declined 14 per cent to 32.6 billion baht, from 37.9 billion baht in Q1 FY2023, on the back of sales volume falling by 15 per cent and a slower-than-expected economic recovery in Thailand and Vietnam.Keppel: Keppel has been appointed to design, build and operate a solar photovoltaic (PV) system on the rooftops of Changi Airport’s terminals, terminal auxiliary structures, airfield and cargo buildings for 25 years, the asset manager announced on Wednesday (Feb 14).In a joint release with Changi Airport Group (CAG), the group announced that the system will have a combined generation capacity of 43 megawatt-peak (MWp), of which 38 MWp will be installed on rooftops.This makes it the largest single-site rooftop solar PV system in Singapore, said the group.Seatrium has renewed its long-term favoured customer contract with two maritime companies to repair, refurbish and upgrade a combined fleet of 43 liquefied natural gas (LNG) carriers docked in South-east Asia.The contracts, inked with GasLog LNG Services and Shell International Trading and Shipping Company, will run from 2024 to 2029, Seatrium said on Wednesday (Feb 14).They were awarded to the group’s wholly owned subsidiary, Seatrium Repairs and Upgrades. It will also support joint planning, information and experience sharing.Civmec: ENGINEERING and construction company Civmec posted a 12.9 per cent increase in net profit to A$31.9 million (S$27.9 million) for the first half ended Dec 31, 2023, on the back of higher revenue.This is up from A$28.2 million in the previous corresponding period, the Australia-headquartered company said in a bourse filing on Wednesday (Feb 14).Earnings per share came in at A$0.0629 compared to A$0.056 in the same period a year earlier.","news_type":1},"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":286404122255576,"gmtCreate":1710957589701,"gmtModify":1710957833391,"author":{"id":"3579080037721963","authorId":"3579080037721963","name":"gyudon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579080037721963","idStr":"3579080037721963"},"themes":[],"htmlText":"","listText":"","text":"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/286404122255576","repostId":"2420474539","repostType":2,"isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":274460230590712,"gmtCreate":1708044686347,"gmtModify":1708045086900,"author":{"id":"3579080037721963","authorId":"3579080037721963","name":"gyudon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579080037721963","idStr":"3579080037721963"},"themes":[],"htmlText":"","listText":"","text":"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/274460230590712","repostId":"1133055268","repostType":2,"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}